Resistance/intolerance to second generation TKIs in CML: what to do next?
If resistance occurs to second generation TKIs in chronic myeloid leukemia (CML) patients, what is the next best option? Here, Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, explores t...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Using inflammation to detect and monitor MDS
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses a new concept in the pathoph...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Benefits of second generation TKIs for CML in the frontline
Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the benefits of second generation TKIs for the frontline treatment of chronic myeloid leukemia (CML). These more potent inhibit...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Improving the treatment landscape for DLBCL patients
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Andrs Ferreri, MD, of IRCCS San Raffaele Hospital, Milan, Italy, describes the ...
Author: VJHemOnc
Added: 09/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel drugs for patients with renal cell carcinoma
Here, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, speaks at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, about how the outcome of patients w...
Author: VJOncology
Added: 09/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Debating the future of prostate cancer management
From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Francesco Montorsi, MD, from Vita-Salute San Raffaele University, Milan, Italy, debates the benefits of abiraterone compared t...
Author: VJOncology
Added: 09/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Goals for precision medicine in NSCLC
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses precision medicine at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. She exp...
Author: VJOncology
Added: 09/04/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 4, 2018 Category: Cancer & Oncology Source Type: podcasts
The reality of implementing TKI therapies for NSCLC in Europe
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses the logistical ...
Author: VJOncology
Added: 08/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Optimizing treatment of ALK+ NSCLC: clinical realities
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses ho...
Author: VJOncology
Added: 08/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Clinical trial data for TKIs in ALK-rearranged NSCLC
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs)...
Author: VJOncology
Added: 08/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy in NSCLC: a perspective
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, provides an overview of recent trial ...
Author: VJOncology
Added: 08/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Increased survival in NSCLC: new considerations
Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, talks about how overall survival has improved in p...
Author: VJOncology
Added: 08/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents
In this interview, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of non-small cell lung cancer (NSCLC) from the 2018 European Lung Cance...
Author: VJOncology
Added: 08/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts
The impact of age in Ph+ and Ph-like ALL
In this video, Robin Fo, MD, from the University of Rome, Rome, Italy, discusses the impact of age on patients with Ph+ or Ph-like acute lymphoblastic leukemia (ALL). This video was recorded at the 2...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
The potential for a chemotherapy-free strategy in ALL
Here, Robin Fo, MD, from the University of Rome, Rome, Italy, discusses the potential of a chemotherapy-free strategy for patients with acute lymphoblastic leukemia (ALL). Speaking from the 2018 Euro...
Author: VJHemOnc
Added: 08/24/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 24, 2018 Category: Cancer & Oncology Source Type: podcasts
